Vensun Pharmaceuticals

About Vensun Pharmaceuticals

Vensun Pharmaceuticals, Inc., established in July 2011 and based in Yardley, Pennsylvania, operates as a generic pharmaceutical company focused on the U.S. market. The company was founded by Hemanshu (Hem) Pandya, who serves as President and CEO, and Kamlesh Haribhakti, the Executive Vice President and Chief Scientific Officer. Mr. Pandya has a background in commercial, operational, and strategic development within the pharmaceutical industry, having held senior roles at companies like IGI Laboratories, Andrx Pharmaceuticals, and Teva Pharmaceuticals. Mr. Haribhakti possesses extensive experience in pharmaceutical development, including formulations and regulatory affairs, and has been responsible for the successful development and FDA approval of over 100 generic products.

Vensun employs an asset-light, partner-driven business model, collaborating with strategic partners to develop and commercialize a portfolio of generic prescription products. This strategy involves developing complex and "difficult to develop" generic drugs across various dosage forms and therapeutic categories. The company's revenue is generated through the marketing and distribution of these pharmaceuticals. Vensun's business approach includes both in-house product development and in-licensing opportunities to expand its pipeline. A significant partnership was established with ScieGen Pharmaceuticals, Inc., to commercialize 23 prescription generic products, where ScieGen handles manufacturing and Vensun manages marketing and distribution.

A major milestone in the company's history occurred in January 2019, when Strides Pharma Science Limited, through its U.S. subsidiary, announced its acquisition of a 100% stake in Vensun. This acquisition was valued at a base consideration of $18 million, with deferred considerations, for a total potential deal amount of up to $93 million. At the time of the acquisition, Vensun had a portfolio of 16 commercialized Abbreviated New Drug Applications (ANDAs) and 13 ANDAs filed with the FDA pending approval. The acquisition was a strategic move for Strides to bolster its U.S. front-end presence and gain access to Vensun's portfolio, including a Competitive Generic Therapy (CGT) designated product with a significant market opportunity. Following the acquisition, Vensun operates as a subsidiary of Strides Pharma Science.